1. A method of treating colon cancer in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I or II, having the structures
wherein:
R1 is selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C12 esters (straight chain or branched) or C1-C12 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C1-C6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, halogen;
n is 2 or 3;
Y is selected from:
a) the moiety:
wherein R7 and R8 are independently selected from the group of H, C1-C6 alkyl, or phenyl optionally substituted by CN, C1-C6 alkyl (straight chain or branched), C1-C6 alkoxy (straight chain or branched), halogen, \u2014OH, \u2014CF3, or \u2014OCF3;
b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of \u2014O\u2014, \u2014NH\u2014, \u2014N(C1C4 alkyl)-, \u2014N\u2550, and \u2014S(O)m\u2014, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H\u2014, \u2014CN\u2014, \u2014CONHR1\u2014, \u2014NH2\u2014, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2R1\u2014, \u2014NHCOR1\u2014, \u2014NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;
c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of \u2014O\u2014, \u2014NH\u2014, \u2014N(C1C4 alkyl)-, \u2014N\u2550, and \u2014S(O)m\u2014, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H\u2014, \u2014CN\u2014, \u2014CONHR1\u2014, \u2014NH2\u2014, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2R1\u2014, \u2014NHCOR1\u2014, \u2014NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;
d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of \u2014O\u2014, \u2014NH\u2014, \u2014N(C1C4 alkyl)-, \u2014N\u2550, and \u2014S(O)m\u2014, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H\u2014, \u2014CN\u2014, \u2014CONHR1\u2014, \u2014NH2\u2014, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2R1\u2014, \u2014NHCOR1\u2014, \u2014NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl; or
e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of \u2014O\u2014, \u2014NH\u2014, \u2014N(C1C4 alkyl)-, and \u2014S(O)m\u2014, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H\u2014, \u2014CN\u2014, \u2014CONHR1\u2014, \u2014NH2\u2014, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2R1\u2014, \u2014NHCOR1\u2014, \u2014NO2, and phenyl optionally substituted with 1-3 (C1-C4)alkyl;
and the pharmaceutically acceptable salts thereof.
2. The method according to claim 1 wherein:
R1 is selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, halogen;
Y is the moiety
R7 and R8 are selected independently from H, C1-C6 alkyl, or combined by \u2014(CH2)p\u2014, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H, \u2014CN, \u2014CONH(C1-C4), \u2014NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2(C1-C4), \u2014NHCO(C1-C4), and \u2014NO2;
or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1, wherein:
R1 is OH;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from the group of Cl, NO2, CN, CF3, or CH3;
Y is the moiety
R7 and R8 are concatenated together as \u2014(CH2)r\u2014, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H, \u2014CN, \u2014CONH(C1-C4), \u2014NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2(C1-C4), \u2014NHCO(C1-C4), and \u2014NO2;
or a pharmaceutically acceptable salt thereof.
4. A method of treating colon cancer in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I or II, having the structures
wherein:
R1 is selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, halogen;
n is 2 or 3; and
Y is the moiety
R7 and R8 are selected independently from H, C1-C6 alkyl, or combined by \u2014(CH2)p\u2014, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H, \u2014CN, \u2014CONH(C1-C4), \u2014NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2(C1-C4), \u2014NHCO(C1-C4), and \u2014NO2;
or a pharmaceutically acceptable salt thereof.
5. The method according to claim 4, wherein:
R1 is OH;
R2, R3, R4, R5, and R6 are independently selected from H, OH or the C1-C4 esters or alkyl ethers thereof, halogen, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH;
X is selected from the group of Cl, NO2, CN, CF3, or CH3;
Y is the moiety
R7 and R8 are concatenated together as \u2014(CH2)r\u2014, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, \u2014CO2H, \u2014CN, \u2014CONH(C1-C4), \u2014NH2, C1-C4 alkylamino, di(C1-C4)alkylamino, \u2014NHSO2(C1-C4), \u2014NHCO(C1-C4), and \u2014NO2;
or a pharmaceutically acceptable salt thereof.
6. The method according to claim 4, wherein the compound is 1-4-(2-azepan-1-yl-ethoxy)-benzyl-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
7. The method according to claim 4, wherein the compound is 2-(4-hydroxy-phenyl)-3-methyl-1-4-(2-piperidin-1-yl-ethoxy)-benzyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A photodetector, comprising:
a light absorbing layer is formed over the semiconductor substrate and a plurality of opening structures.
2. The photodetector according to claim 1, wherein said light absorbing layer is selected from the group consisting of gold (Au), silver (Ag), aluminum (Al), copper (Cu), titanium (Ti), nickel (Ni), platinum (Pt), chromium (Cr), tungsten (W), molybdenum (Mo), and cobalt (Co).
3. The photodetector according to claim 1, wherein said light absorbing layer is selected from the group consisting of platinum-silicon compound (PtxSi), nickel-silicon compound (NixSi), titanium-silicon compound (TixSi), cobalt-silicon compound (CoxSi), tungsten-silicon compound (WxSi) and molybdenum-silicon compound (MoxSi), where x is an arbitrary number representing a ratio of metal and silicon.
4. The photodetector according to claim 1, wherein said plurality of opening structures are selected from the group consisting of a periodic structure and a non-periodic structure.
5. The photodetector according to claim 1, wherein said absorbing layer formed across at least two opening structures.
6. A photodetector, comprising:
a semiconductor substrate; and
a light absorbing layer is formed over the semiconductor substrate and a plurality of opening structures.
7. The photodetector according to claim 6, wherein said light absorbing layer comprises a metal layer.
8. The photodetector according to claim 7, wherein said metal layer is selected from the group consisting of gold (Au), silver (Ag), aluminum (Al), copper (Cu), titanium (Ti), nickel (Ni), platinum (Pt), chromium (Cr), tungsten (W), molybdenum (Mo), and cobalt (Co).
9. The photodetector according to claim 6, wherein said light absorbing layer comprises a silicide layer.
10. The photodetector according to claim 9, wherein said silicide layer is selected from the group consisting of platinum-silicon compound (PtxSi), nickel-silicon compound (NixSi), titanium-silicon compound (TixSi), cobalt-silicon compound (CoxSi), tungsten-silicon compound (WxSi) and molybdenum-silicon compound (MoxSi), where x is an arbitrary number representing a ratio of metal and silicon.
11. The photodetector according to claim 6, wherein said plurality of opening structures are selected from the group consisting of a periodic structure and a non-periodic structure.
12. The photodetector according to claim 6, wherein said absorbing layer formed across at least two opening structures.
13. A photodetector, comprising:
a semiconductor substrate, said semiconductor substrate comprising a plurality of opening structures; and
a light absorbing layer, said light absorbing layer is formed over the semiconductor substrate and a plurality of opening structures.
14. The photodetector according to claim 13, wherein said light absorbing layer comprises a metal layer.
15. The photodetector according to claim 14, wherein said metal layer is selected from the group consisting of gold (Au), silver (Ag), aluminum (Al), copper (Cu), titanium (Ti), nickel (Ni), platinum (Pt), chromium (Cr), tungsten (W), molybdenum (Mo), and cobalt (Co).
16. The photodetector according to claim 13, wherein said light absorbing layer comprises a silicide layer.
17. The photodetector according to claim 16, wherein said silicide layer is selected from the group consisting of platinum-silicon compound (PtxSi), nickel-silicon compound (NixSi), titanium-silicon compound (TixSi), cobalt-silicon compound (CoxSi), tungsten-silicon compound (WxSi) and molybdenum-silicon compound (MoxSi), where x is an arbitrary number representing a ratio of metal and silicon.
18. The photodetector according to claim 13, wherein said plurality of opening structures are selected from the group consisting of a periodic structure and a non-periodic structure.
19. The photodetector according to claim 13, wherein said absorbing layer formed across at least two opening structures.